Wave Life Sciences announced positive Phase 1 results for WVE-007, an RNA-based drug targeting fat loss without muscle loss in obesity treatment. The drug showed durable reductions in Activin E and improved body composition with a good safety profile. Ongoing Phase 2a trials are testing higher doses in individuals with higher BMI and adiposity, with six-month data expected in 2027. Wave is also studying WVE-007 combined with tirzepatide to enhance fat loss and plans to integrate maintenance trials to accelerate development.
Wave Life Sciences' WVE-007 progress is the subject, with Pluang data showing that among 150 priced Health-sector US stocks, 99 rose and 43 fell today. Notable movers include MRVI at USD 7.83 (+1.95%), ACAD at USD 18.48 (+1.87%) with 98% sell order activity, and COGT at USD 28.62 (-1.78%) with 61% buy order activity. This snapshot is as of Nov 13, 2026 19:41 WIB.
Michelin has announced the total number of its voting rights and shares as of October 31, 2026. The company has 691,516,292 shares and 960,075,649 voting rights, considering 20,287,710 treasury shares. This disclosure complies with French regulations...
Michelin has disclosed the total number of voting rights and shares composing its capital as of October 31, 2026. The company reported 691,516,292 shares, with theoretical voting rights totaling 980,363,359 and exercisable voting rights at 960,075,64...
KeyBanc lowered its price target for YETI Holdings to $49, suggesting a 27.94% upside from the current $38.30 stock price. This follows YETI's reduction of its full-year adjusted sales growth forecast to about 6% from the previous 7-8%, citing consum...
Bernstein SocGen Group has reduced its price target for Applied Materials to $600, even though the company reported higher sales and profits in Q4 2026 driven by strong demand for semiconductor services, especially AI chips. Applied Materials posted ...
Boralex Inc. announced a private placement of $600 million Canadian dollars in green bonds, split into two series maturing in 2031 and 2036 with interest rates of 4.503% and 5.173%, respectively. This marks Boralex's first issuance of green corporate...
